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Objective. Control outcomes and exposures can improve internal validity of nonran-
domized studies by assessing residual bias in effect estimates. Control outcomes are
those expected to have no treatment effect or the opposite effect of the primary out-
come. Control exposures are treatments expected to have no effect on the primary out-
come. We review examples of control outcomes and exposures from prior studies and
provide recommendations for conducting and reporting these analyses.
Data Sources and Study Design. Review in Google Scholar and Medline of
research studies employing control outcomes or exposures. We abstracted publication
year, control outcome, control exposure, primary outcome, primary exposure, control
outcome/exposure effect, proposed source of bias, and causal criteria.
Principal Findings. There is inconsistent terminology for these concepts, making
study identification challenging. Six of 11 studies found null associations between treat-
ments and negative control outcomes/exposures, providing greater confidence that the
primary study findings were not biased. Five studies found unexpected associations,
suggesting bias in the primary association.
Conclusions. The rigor of nonrandomized studies can be improved with inclusion of
control outcomes and exposures for bias detection. Given ongoing concern about clini-
cal and policy inferences from nonrandomized studies, we recommend adoption of
these measurement tools.
Key Words. Control outcomes, control exposures, falsification tests,
nonequivalent outcomes, nonequivalent exposures
There is an ongoing debate about the evidentiary value of nonrandomized
study results. Much of this has stemmed from the controversy surrounding the
Women’s Health Initiative trial of hormone replacement therapy and risk for
coronary heart disease (Manson et al. 2003). Although other efforts have
demonstrated that well-conducted nonrandomized studies can generate





results equivalent with randomized trials (Benson and Hartz 2000; Concato,
Shah, and Horwitz 2000; Furlan et al. 2008; Hernan et al. 2008), this perspec-
tive is far from universally shared because several meta-analyses have
reported substantial discordance between randomized and nonrandomized
studies (Ioannidis et al. 2001; Ioannidis 2005).
Efforts have been made in recent years to address concerns regarding
the internal validity of nonrandomized studies, including the widespread
adoption of new-user designs (Ray 2003), use of sample restriction (Schnee-
weiss et al. 2007), and use of statistical methods such as propensity scores,
instrumental variables, and marginal structural models. These statistical tools
are often a last resort, because internal validity threats of selection bias (also
known as unobserved confounding) were not addressed via study design or
measurement strategies. Further, any assessment of causality in a nonrandom-
ized study relies on assumptions about statistical models and their specifica-
tion that must be guided by subject-matter knowledge (Robins 2001; Hernan
et al. 2002). Researchers using secondary data for comparative effectiveness
research have to address limitations regarding a lack of information on known
confounders (since known confounders may be unmeasured) and potential
gaps in subject-matter knowledge that reduce the likelihood of estimating cau-
sal effects without bias (Brookhart et al. 2010b).
Nevertheless, researchers may have adequate subject-matter knowledge
to be able to identify outcomes that are not expected to change in response to
the intervention of interest, which have been referred to as control outcomes
or nonequivalent outcomes. Inclusion of control outcomes in nonrandomized
studies can be a potentially useful strategy for detecting selection bias by
expanding the measurement set beyond outcomes expected to change in
response to the exposure or treatment of interest. Researchers may also be
able to identify treatments that are known to be unrelated to the primary out-
come (analogous to placebos). These control exposures are additional tools
that researchers could use to assess selection bias, as is routinely done in the
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economics literature (Basker 2005; Holmlund, McNally, and Viarengo 2010;
Rothstein 2010). Unfortunately, control outcomes and control exposures are
under-utilized in nonrandomized comparative effectiveness research,
although their use and advantages in this area have been described previously
(Brookhart et al. 2010a; Lipsitch, Tchetgen Tchetgen, and Cohen 2010; Pra-
sad and Jena 2013).
The purpose of this paper is to introduce control outcomes and
exposures to a wider audience by summarizing illustrative examples from
prior studies, which may provide readers with insights for identification of
control outcomes and exposures in their own work. We conclude with
recommendations for the conduct and reporting of studies that employ
control outcomes or exposures, and present a framework for identifying
them using Sir Austin Bradford Hill’s factors for assessing causation (Hill
1965). We expect this overview to be of interest to researchers, manu-
script reviewers, and grant reviewers seeking to improve the rigor and
internal validity of comparative effectiveness research studies using non-
randomized study designs.
METHODS
To identify published studies that employed control outcomes or exposures,
we searched MEDLINE (via PubMed) and Google Scholar for manuscripts
that included terms related to control outcomes, control exposures, falsifica-
tion endpoints, falsification tests, and nonequivalent outcomes or exposures.
We also included articles previously known or produced by the study team
that were not identified in our prior search since there are no Medical Subject
Heading (MeSH) terms for control outcomes or control exposures. We then
manually searched bibliographies and works citing selected articles and con-
sulted with colleagues to guide further study selection.
Identified studies were retained if they clearly identified the control out-
come or exposure on the basis of its stated purpose for inclusion in the analy-
sis. From our search we identified 11 studies that utilized control outcomes,
control exposures, or both (Table 1). For each of these studies, we abstracted
the following information: year of publication, control outcome, control expo-
sure, primary study endpoint, primary study exposure/treatment, primary
study effect measure, control outcome effect, control exposure effect, the pro-
posed source of bias (if named), and the causal criteria (if known). We used this
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information to summarize results from eight studies that used control out-
comes, two studies that used control exposures, and one study that used both.
RESULTS
Studies Using Control Outcomes
Control outcomes can be either negative (i.e., outcomes known to be unaf-
fected by the treatment under study) or positive (i.e., outcomes known to be
affected by treatment). The nine studies that used negative control outcomes
chose outcomes that were not anticipated to be related to exposure (McClellan,
McNeil, and Newhouse 1994; Redelmeier, Scales, and Kopp 2005; Jackson
et al. 2006; Brookhart et al. 2007; Rasmussen, Chong, and Alter 2007; Mauri
et al. 2008; Maciejewski et al. 2010; Patrick et al. 2011; Jena, Sun, and Gold-
man 2013) and were sorted into two groups. Four studies found that the associ-
ation of the treatment with the negative control outcome was null (as expected)
and provided greater confidence that the treatment effect/association with the
primary outcome was not biased by unobserved confounding (Redelmeier,
Scales, and Kopp 2005; Rasmussen, Chong, and Alter 2007; Mauri et al.
2008; Maciejewski et al. 2010). Five studies found that the treatment was unex-
pectedly associated with the negative control outcomes, which raised concerns
about residual bias in the treatment effect/association on the primary outcome
(McClellan, McNeil, and Newhouse 1994; Jackson et al. 2006; Brookhart et al.
2007; Patrick et al. 2011; Jena, Sun, and Goldman 2013).
Studies by Redelmeier, Mauri, Rasmussen, andMaciejewski were repre-
sented by this first group. Redelmeier, Scales, and Kopp (2005) compared the
risk of acute myocardial infarction (AMI) or death among patients receiving
either atenolol or metoprolol following elective surgery. They included sev-
eral postsurgical noncardiac complications (wound infection, ileus, pneumo-
nia, aspiration, respiratory failure, renal failure, delirium) as negative control
outcomes and found no differences in these negative controls by beta-blocker
received. Mauri et al. (2008) compared mortality, myocardial infarction (MI),
and target-vessel revascularization within 2 years among patients receiving a
drug-eluding stent or a bare metal stent. Mortality during the first 2 days fol-
lowing stent placement was the negative control outcome, since benefits of
using one therapy over the other would not be expected in the immediate
postsurgery period. They found no differences in 2-day mortality as expected,
so concluded that the association between treatment and primary outcome
was unconfounded.
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Rasmussen, Chong, and Alter (2007) compared long-term mortality post-
AMI among patients with high, intermediate, and low levels of adherence to
statins or beta-blockers. They included cancer-related hospital admissions as a
control outcome as adherence to statins or beta-blockers was not hypothesized
to increase this risk. As expected, they found no association between treatment
adherence and cancer hospitalizations, suggesting that healthy adherer bias was
not likely to be influencing their findings. Finally, Maciejewski et al. (2010)
evaluated the impact of a value-based insurance design scheme (lower prescrip-
tion drug copayments) on refill adherence to angiotensin-converting-enzyme
(ACE) inhibitors, beta-blockers, calcium channel blockers, statins, and diuret-
ics, comparing patients in plans that did and did not implement copayment
changes. Angiotensin receptor blockers and cholesterol absorption inhibitors
were the negative control outcomes because copayment changes for these
drugs were comparable between patients in the two arms. As expected, they
found no difference in adherence to these drugs, so concluded that the associa-
tion between copayment reduction and increased refill adherence to the other
drugs was unconfounded.
The studies by McClellan, Jackson, Brookhart, Patrick, and Jena were
represented by the second group in which the treatment was unexpectedly
associated with the negative control outcomes. The study by McClellan,
McNeil, and Newhouse (1994) evaluated the impact of cardiac catheteriza-
tion on mortality within 4 years following an AMI. They utilized mortality
at 1 day post-AMI as a negative control outcome, hypothesizing that effects
appearing on the first day post-AMI were unlikely to be related to catheteri-
zation and revascularization but to other aspects of treatment that correlated
with the procedures. Unlike the null finding of a similar “early effect of treat-
ment” from the Mauri study, they found a significant difference in 1-day
mortality, indicating residual confounding.
Next, Jackson et al. (2006) evaluated the impact of influenza vaccination
on mortality and influenza/pneumonia-related hospitalizations during influ-
enza season. They used hospitalizations for injury or trauma during influenza
season as their primary negative control outcomes. In a novel use of timing as
a negative control outcome, they also used mortality and influenza/pneumo-
nia-related hospitalizations in the pre-influenza season as a negative control
outcome because influenza vaccination was not expected to affect these out-
comes before influenza season started. They found that influenza vaccination
was negatively associated with (i.e., protective against) hospitalizations for
injuries and trauma during influenza season and with mortality and influenza/
pneumonia-related hospitalizations in the pre-influenza season. These unex-
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pected findings suggested that the association between influenza vaccination
and mortality and influenza/pneumonia-related hospitalizations during influ-
enza season was likely confounded.
The two papers by Brookhart et al. (2007) and Patrick et al. (2011) used
the occurrence of burns, asthma, and gastrointestinal bleeding as negative
control outcomes when evaluating the effect of statins and statin adherence.
They argued that there is no biologically plausible rationale or causal pathway
through which statins would impact the likelihood of these negative control
outcomes (Patrick et al. 2011). Thus, significant associations between statins
and these negative control outcomes could suggest residual confounding in
the relationship between statins and other outcomes of interest (e.g., mortality)
in prior studies (Aronow et al. 2001; Stenestrand and Wallentin 2001). They
found significant differences in multiple control outcomes, including
increased preventative services use (bone mineral density testing, fecal-occult
blood tests, mammography, and influenza and pneumonia vaccinations) and
clinical outcomes (asthma, burns, falls, fractures, motor vehicle accidents,
wounds, gastrointestinal bleeding, skin infections) for patients who were
adherent to statins, suggesting that other outcomes were likely confounded via
healthy adherer/healthy user bias.
Finally, Jena, Sun, and Goldman (2013) evaluated the incidence of com-
munity acquired pneumonia among patients who did and did not use proton
pump inhibitors (PPIs). They selected several negative control outcomes that
had no biologically plausible relationship with PPIs, including osteoarthritis,
chest pain, urinary tract infections, deep vein thrombosis, skin infections, and
rheumatoid arthritis. They found associations between each of the selected
outcomes and PPIs, suggesting that there was possible confounding by indica-
tion or disease severity that was unaccounted for in their study.
It should be noted that these five papers, in which the treatment was
unexpectedly associated with the negative control outcomes did not then
attempt to statistically adjust for this evidence of unobserved confounding.
Instead, each of these papers noted that the treatment effect on the primary out-
come was likely biased, and that future work was needed to improve upon these
estimates given significant treatment effects/associations in the primary outcome.
Studies Using Control Exposures
An additional approach to improving the internal validity of nonrandomized
studies is to use control exposures, which are treatments that are expected to
have no effect on the outcome of interest (analogous to a placebo). We
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identified three studies in our review that used negative control exposures
(Table 2). Zaadstra et al. (2008) evaluated childhood infections that could be
possible causes of multiple sclerosis. To address the possibility of recall bias in
their patient survey, they used several negative control exposures, including
broken arms, concussions, and tonsillectomy. Two of the negative control
exposures (concussions and tonsillectomy) were associated with the later
development of multiple sclerosis, which they interpreted as evidence of recall
bias since neither childhood event was plausibly related to multiple sclerosis.
Dusetzina et al. (2013) used aromatase inhibitor initiators as the nega-
tive control exposure when evaluating the effect of an FDA label change tar-
geting drug interaction risks between strong CYP2D6 inhibitor
antidepressants and tamoxifen. In this example, the drug interaction risk
exists only for tamoxifen-treated patients as aromatase inhibitors are metabo-
lized outside of the CYP2D6 pathway. Changes in the use of strong inhibitor
antidepressants (the primary outcome) among tamoxifen users could then be
estimated while controlling for broader changes in antidepressant use over
time among women using endocrine therapy. The authors observed greater
decreases in strong CYP2D6 inhibitor antidepressant use among individuals
prescribed tamoxifen, suggesting that the label change related to CYP2D6
risk resulted in selective prescribing of therapies and not general reductions
in strong inhibitor antidepressants.
Finally, Rasmussen, Chong, and Alter (2007) evaluated the impact of
varying levels of adherence to statins and beta-blockers on long-term mortal-
ity following AMI. The authors used adherence to calcium channel blockers
as a control exposure as these treatments have no biologically plausible effect
on post-AMI mortality. They compared three levels of adherence to each
therapy and found patients with intermediate and lower adherence to statins
were at increased risk of mortality as compared with patients with high
adherence. Similar trends were observed for patients taking beta-blockers.
They found no association between adherence to calcium channel blockers
and mortality, suggesting that healthy user bias was minimized in their study
and the protective effect of high statin adherence against mortality was unli-
kely to be confounded.
DISCUSSION
Control outcomes and exposures can improve the internal validity of nonex-
perimental studies because in certain situations they can detect confounding
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and selection bias via measurement of whether the treatment effect in the out-
come of interest is confounded by unexpected factors (Brookhart et al. 2010a;
Lipsitch, Tchetgen Tchetgen, and Cohen 2010). This direct assessment is an
appealing feature of using control outcomes as measurement tools because
they may be easier to implement in practice than statistical tools like instru-
mental variables. Of the 11 peer-reviewed studies we summarize that incorpo-
rated control outcomes or exposures to evaluate bias, six of them found a null
association between treatment and the selected negative control outcomes or
exposure. The null association where expected provided greater confidence
in the validity of significant associations of interest (also where expected).
However, five studies found unexpected associations for the selected control
outcomes or exposures, which suggest that the primary association of interest
may be biased.
Inclusion of control outcomes in nonrandomized studies is also appeal-
ing when there is interest in making causal claims because control outcomes
impose a higher threshold for rejecting the null hypothesis than exists for non-
randomized studies without them. In nonrandomized studies that include con-
trol outcomes or exposures, the null hypothesis of no association between
treatment and primary outcome of interest can only be rejected if treatment is
significant in the outcome equation of interest and one fails to reject the null in
a control outcome or exposure. Control outcomes can also be used to assess
the potential for recall bias in surveys, although we found few examples of this
application. Given their utility, control outcomes have been recommended in
guidance on the design of prospective nonrandomized studies (Berger et al.
2012, 2014).
Proposed Framework for Identifying Control Exposures or Outcomes
Given the theoretical utility of these measurement tools, one must identify a
potentially valid control outcome or control exposure a priori. This requires
subject-matter knowledge and consideration of the causal criteria in the spe-
cific analysis under consideration. Application of formal criteria to this task
can aid in identification of valid control outcomes or control exposures, partic-
ularly when there is an interest in estimating the causal association between an
exposure and primary outcome.
Some of the best known epidemiologic criteria for evaluating the cause
and effect relationship were summarized by Hill (1965). The criteria outlined
for identifying a causal relationship between an exposure and outcome can be
readily adapted and used as a framework for identifying control exposures or
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outcomes. In particular, Hill’s criteria for (biological) plausibility, temporality,
specificity, consistency, and analogy seem most appropriate for this applica-
tion (Table 3). For medical product evaluations, the criteria of temporality and
biological plausibility may be the most familiar to researchers.
We found that these two criteria were most commonly employed by
researchers for justification for the selection of controls, with the Jackson study
providing a particularly thoughtful application of the temporality and biologi-
cal plausibility criteria. If vaccination is expected to reduce influenza/pneu-
monia-related hospitalizations only during influenza season, then one might
reasonably assume that vaccination should have no impact on these hospital-
izations in the pre-influenza season due to biological implausibility and timing
criteria. As a further robustness check for unobserved confounding, Jackson
and colleagues also assessed a second set of outcomes that did not have biolog-
ical plausibility for association with vaccination: hospitalizations for injury or
trauma during influenza season. The only plausible way in which influenza/
pneumonia vaccination could affect hospitalizations for injury or trauma
would be through unobserved confounding. However, Jackson and col-
Table 3: Bradford-Hill Criteria to ConsiderWhen Identifying Control
Outcomes or Exposures
Criteria Description
Strength The larger the association, the more likely that the association is causal.
However, a small association does not mean that there is not a causal effect as
expected treatment effects in medicine are often small.
Consistency Findings have been replicated by other researchers and/or in different samples.
Specificity Themore specific an association between a factor and an effect is, the greater
the probability of a causal relationship. Causation is likely if the association is
identified under specific circumstances and that there is no other likely
explanation.
Temporality Cause precedes effect; if there is an expected delay between the cause and
expected effect, then the effect must occur after that delay.
Biological
Gradient
For exposures that follow a dose-response curve, greater exposure should
generally lead to greater incidence of the effect. In some cases, the mere
presence of the factor can trigger the effect. In other cases, an inverse
proportion is observed: greater exposure leads to lower incidence.
Plausibility A plausible biological mechanism between cause and effect is helpful.
Coherence Coherence between epidemiological and laboratory findings increases the
likelihood of an effect. Results need to be interpreted in light of existing data
and known facts of the natural history and disease biology.
Experiment Reducing exposure to the risk factor reduces the likelihood of the outcome.
Analogy Exposures with similar mechanisms of actionmay result in similar outcomes.
Control Outcomes and Exposures 1445
leagues did not then re-analyze their primary outcomes and these control out-
comes after accounting for unobserved confounding via covariate adjustment
or statistical methods. Only through this additional step would it be possible
to know whether the association between influenza/pneumonia vaccination
and the control outcomes converged to the null after initial detection of unob-
served confounding. Nonetheless, the analysis by Jackson was a creative appli-
cation of the timing and biological plausibility criteria for identification of
control outcomes.
Although not all criteria are appropriate for control identification in
every setting, this framework may be a useful starting place for identifying
controls. Importantly, proper control selection requires that the researcher
understand the mechanism of potential confounding and that he or she selects
a control that is subject to the same confounding mechanism but is not
impacted by the treatment of interest. Suppose a researcher is studying the
effect of statins on mortality following MI and is concerned that this treatment
effect may be prone to healthy user bias. To test this possibility, the researcher
should select a control outcome that has been associated with patient health
behaviors but that is not influenced by statin use. Selecting a control outcome
or exposure that is unrelated to patient health behaviors (for example, kidney
stones or diverticulitis) (Dormuth et al. 2009) does not provide a robust test
because these control outcomes are not likely impacted by the confounding
mechanism (healthy user bias) that is potentially biasing the effect of statins on
post-MI mortality. Thus, a null finding of statins on these control outcomes
would provide the researcher with a false sense of confidence that the effect of
statins on post-MI mortality was not subject to healthy user bias. Clinical judg-
ment—particularly knowledge of the disease process—will often be critical
for selection of control outcomes or control exposures that serve their stated
purpose.
Recommendations for Reporting
We suggest that researchers using control outcomes and exposures should
explicitly identify these measures in the methods sections of their manuscripts
and include a rationale for their inclusion. Further, researchers should report
results of all a priori selected controls, regardless of their consistency or lack
thereof with the investigators’ hypothesis.
Next, we recommend that terminology be standardized to improve the
recognition of these measures. Terms that have been previously employed to
describe these measures include “falsification endpoints,” “non-equivalent
1446 HSR: Health Services Research 50:5 (October 2015)
controls/exposures,” and “control outcomes/exposures.”We recommend the
use of “control outcomes” or “control exposures”with specification of the pro-
posed direction of the effect (e.g., negative or positive). Further, we recom-
mend the creation of a MeSH term for improving the identification of the use
of these measurement tools in nonrandomized studies. This would benefit
researchers since these measurement tools are likely to be used increasingly
over time to improve the rigor and internal validity of comparative effective-
ness research. Easier identification of studies using control outcomes and
exposures will allow for further evaluation of the adoption of these tools and
assessments of the quality of reporting of their use.
We identified a limited number of papers for inclusion in this review
since these measures tend to be reported within the manuscript text and not in
fields used for keyword identification within PubMed. As a result, we may
have excluded other papers that faithfully applied control outcomes or control
exposures to great effect. As these measurement tools become more widely
used and easier to systematically identify, it will be useful to examine ways in
which residual confounding has been addressed upon its identification in stud-
ies that find evidence of confounding via these tools.
CONCLUSION
Control outcomes and exposures are important tools for evaluating the inter-
nal validity of nonrandomized study findings. Routine use of controls will
increase the rigor of studies by helping to identify studies where residual con-
founding is a concern (when control findings are not consistent with the
researcher’s hypothesis) or they may act as confirmation of study findings
(when control findings are consistent with the researcher’s hypothesis). Their
use will create a higher threshold for rejecting the null hypothesis in an associ-
ation of interest by requiring rejection of the null in the outcome equation of
interest and failure to reject the null in a control outcome or exposure. Given
the ongoing concern about clinical and policy inferences from nonrandom-
ized studies, it seems reasonable to more widely employ these measurement
tools.
This paper was developed for researchers conducting nonrandomized
comparative effectiveness research who are unfamiliar with these nonequiva-
lent outcomes. As these studies undergo continued scrutiny and investigators
need to increase the validity of their nonrandomized studies, the use of tools
to increase validity will be important.
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